In vivo targeting of SF/HGF and c-met expression via U1snRNA/ribozymes inhibits glioma growth and angiogenesis and promotes apoptosis
- PMID: 11729097
- DOI: 10.1096/fj.01-0421fje
In vivo targeting of SF/HGF and c-met expression via U1snRNA/ribozymes inhibits glioma growth and angiogenesis and promotes apoptosis
Abstract
The multifunctional growth factor scatter factor/hepatocyte growth factor (SF/HGF) and its receptor c-met have been implicated in the genesis, malignant progression, and chemo/radioresistance of multiple human malignancies, including gliomas. We examined the antitumor effects of targeting SF/HGF and c-met expression in pre-established glioma xenografts by using novel chimeric U1snRNA/ribozymes. Transient expression of anti-SF/HGF and anti-c-met U1snRNA/ribozymes inhibited SF/HGF and c-met expression, c-met receptor activation, tumor cell migration, and anchorage-independent colony formation in vitro. Delivery of U1snRNA/ribozymes to established subcutaneous glioma xenografts via liposome-DNA complexes significantly inhibited tumor growth as well as tumor SF/HGF and c-met expression levels. Histologic analysis of tumors treated with U1snRNA/ribozymes showed a significant decrease in blood vessel density, an increase in activation of the pro-apoptotic enzyme caspase-3, and an increase in tumor cell apoptosis. Treatment of animals bearing intracranial glioma xenografts with anti-SF/HGF and anti-c-met U1snRNA/ribozymes by either intratumoral injections of adenoviruses expressing the transgenes or intravenous injections of U1snRNA/ribozyme-liposome complexes substantially inhibited tumor growth and promoted animal survival. We demonstrate that SF/HGF and/or c-met expression can be targeted in vivo to inhibit tumor growth. In addition, our findings represent the first in vivo application of chimeric U1snRNA/ribozymes, which have numerous potential therapeutic gene-targeting applications.
Similar articles
-
Targeting the c-Met pathway potentiates glioblastoma responses to gamma-radiation.Clin Cancer Res. 2005 Jun 15;11(12):4479-86. doi: 10.1158/1078-0432.CCR-05-0166. Clin Cancer Res. 2005. PMID: 15958633
-
Reversion of human glioblastoma malignancy by U1 small nuclear RNA/ribozyme targeting of scatter factor/hepatocyte growth factor and c-met expression.J Natl Cancer Inst. 1999 Sep 15;91(18):1548-56. doi: 10.1093/jnci/91.18.1548. J Natl Cancer Inst. 1999. PMID: 10491431
-
The scatter factor/hepatocyte growth factor: c-met pathway in human embryonal central nervous system tumor malignancy.Cancer Res. 2005 Oct 15;65(20):9355-62. doi: 10.1158/0008-5472.CAN-05-1946. Cancer Res. 2005. PMID: 16230398
-
Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis.Neuro Oncol. 2005 Oct;7(4):436-51. doi: 10.1215/S1152851705000050. Neuro Oncol. 2005. PMID: 16212809 Free PMC article. Review.
-
c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention.Cancer Lett. 2005 Jul 8;225(1):1-26. doi: 10.1016/j.canlet.2004.09.044. Epub 2004 Nov 11. Cancer Lett. 2005. PMID: 15922853 Review.
Cited by
-
Getting into the brain: liposome-based strategies for effective drug delivery across the blood-brain barrier.Int J Nanomedicine. 2016 Oct 18;11:5381-5414. doi: 10.2147/IJN.S117210. eCollection 2016. Int J Nanomedicine. 2016. PMID: 27799765 Free PMC article. Review.
-
Targeting HGF/c-Met Axis Decreases Circulating Regulatory T Cells Accumulation in Gastric Cancer Patients.Cancers (Basel). 2021 Nov 5;13(21):5562. doi: 10.3390/cancers13215562. Cancers (Basel). 2021. PMID: 34771724 Free PMC article.
-
EGFRvIII and c-Met pathway inhibitors synergize against PTEN-null/EGFRvIII+ glioblastoma xenografts.Mol Cancer Ther. 2009 Jul;8(7):1751-60. doi: 10.1158/1535-7163.MCT-09-0188. Epub 2009 Jul 7. Mol Cancer Ther. 2009. PMID: 19584231 Free PMC article.
-
HGF/c-met system targeting PI3K/AKT and STAT3/phosphorylated-STAT3 pathways in pituitary adenomas: an immunohistochemical characterization in view of targeted therapies.Endocrine. 2013 Dec;44(3):735-43. doi: 10.1007/s12020-013-9950-x. Epub 2013 Apr 11. Endocrine. 2013. PMID: 23576023
-
MET Inhibition Results in DNA Breaks and Synergistically Sensitizes Tumor Cells to DNA-Damaging Agents Potentially by Breaching a Damage-Induced Checkpoint Arrest.Genes Cancer. 2010 Oct;1(10):1053-62. doi: 10.1177/1947601910388030. Genes Cancer. 2010. PMID: 21779429 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous